To evaluate the prognostic accuracy of SYCP2 expression in regions of HPV+ in situ carcinoma, we constructed a receiver operating characteristic (ROC) curve (Figs. S8,S9). This evidence concerns the gene SYCP2 and in situ carcinoma.